1. Poor prognosis of mediastinal non-Hodgkin's lymphoma with an immature phenotype of CD2+, CD7 (or CD5)+, CD3-, CD4-, and CD8-.
- Author
-
Yumura-Yagi K, Ishihara S, Hara J, Murata M, Izumi Y, Tawa A, Sato A, Matsumoto Y, Kozaiwa K, and Nishida M
- Subjects
- Adolescent, Child, Child, Preschool, Cytarabine administration & dosage, Female, Humans, Lymphoma, Non-Hodgkin immunology, Lymphoma, Non-Hodgkin mortality, Male, Mediastinal Neoplasms immunology, Mediastinal Neoplasms mortality, Neoplasm Recurrence, Local, Phenotype, Prognosis, Remission Induction, Antigens, Differentiation, T-Lymphocyte analysis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Non-Hodgkin drug therapy, Mediastinal Neoplasms drug therapy
- Abstract
Nine children with mediastinal non-Hodgkin's lymphoma (NHL) were treated according to our new regimen which is characterized by intensified therapy with high-dose cytosine arabinoside (HDCA). After induction therapy with a combination of five drugs, such as vincristine, doxorubicin, cyclophosphamide, 1-asparaginase, and prednisolone, intermediate dosages of methotrexate (MTX) (1 g/m2) and HDCA (1.5 g/m2 x 12 doses) were administered. All but one patient (88.9%) achieved complete remission and then received this intensified therapy. With a median follow-up period of 25.5 months, five patients are still in complete remission, but three patients have relapsed. From the phenotypic point of view, these relapsed patients showed only very immature T-cell differentiation antigens such as CD2 and CD7 (or CD5). These results suggest that HDCA as intensified therapy for children with mediastinal NHL seems to be effective. However, for patients with an immature phenotype of T-lineage cells, more sophisticated regimens should be prepared.
- Published
- 1989
- Full Text
- View/download PDF